Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features

Chinese Journal of Cancer

Volumn 32, Issue 6, 2013, Pages 303-311

  Sircar, Kanishka ^a   Rao, Priya ^a   Jonasch, Eric ^a   Monzon, Federico A ^b   Tamboli, Pheroze ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clear cell renal carcinoma; Fluorescence in situ hybridization; Hybrid oncocytic tumors; Immunohistochemistry; Papillary renal carcinoma; Renal cell carcinoma

Indexed keywords

ANGIOGENESIS INHIBITOR;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHROMOPHOBE RENAL CELL CARCINOMA; CHROMOSOME ABERRATION; CLEAR CELL PAPILLARY RENAL CELL CARCINOMA; CYTOGENETICS; GENE MUTATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CARCINOMA; NEEDLE BIOPSY; PAPILLARY RENAL CELL CARCINOMA; RENAL ONCOCYTOMA; REVIEW; XP11 TRANSLOCATION RENAL CELL CARCINOMA;

BIOPSY, LARGE-CORE NEEDLE; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; HUMANS; KIDNEY NEOPLASMS;

EID: 84878915825     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10136     Document Type: Review

References (45)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer, 2012,127:2893-2917
2. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 2007,109:2257-2267
3. FDA Approval for Temsirolimus. 2011Available from: http://www.cancer.gov/cancertopics/druginfo/fda-temsirolimus.
4. FDA Approval for Everolimus. 2012 Available from: http://www.cancer.gov/cancertopics/druginfo/fda-everolimus.
5. Hagenkord JM, Gatalica Z, Jonasch E, et al. Clinical genomics of renal epithelial tumors. Cancer Genet, 2011,204:285-297
6. Oberling C, Riviere M, Haguenau F. Ultrastructure of the clear cells in renal carcinomas and its importance for the demonstration of their renal origin. Nature, 1960,186:402-403
7. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol, 1985,48:207-217
8. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol, 1997, 183:131-133
9. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol, 2003,162:925-932
10. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol, 2003,27:612-624
11. Oosterwijk E, Rathmell WK, Junker K, et al. Basic research in kidney cancer. Eur Urol, 2011,60:622-633
12. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A, 1997,94:8104-8109
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007,356:115-124
14. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2afor treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007,370:2103-2111
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007,356:125-134
16. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010,28:1061-1068
17. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 2012,378:1931-1939
18. Ficarra V, Martignoni G, Galfano A, et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol, 2006,50:786-793; discussion 793-794
19. Sika-Paotonu D, Bethwaite PB, McCredie MR, et al. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol, 2006,30:1091-1096
20. Bex A, Larkin J, Blank C. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities. Curr Oncol Rep, 2011,13:240-248
21. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol, 2006,30:141-153
22. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol, 2008,32:1239-1245
23. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol, 2010,34: 1608-1621
24. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia- inducible factor pathway-related proteins. Mod Pathol, 2011,24: 1207-1220
25. Adam J, Couturier J, Molinie V, et al. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-gr ade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology, 2011,58:1064-1071
26. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology, 2010,42:369-373
27. Silberstein J, Grabowski J, Saltzstein SL, et al. Renal cell carcinoma in the pediatric population: results from the California Cancer Registry. Pediatr Blood Cancer, 2009,52: 237-241
28. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol, 2007,31:1149-1160
29. Ramphal R, Pappo A, Zielenska M, et al. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol, 2006,126:349-364
30. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol, 2001,159:179-192
31. Medendorp K, van Groningen JJ, Schepens M, et al. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas. Cytogenet Genome Res, 2007,118:157-165
32. Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res, 2009,15:1170-1176
33. Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t (X;1) (p11.2;q21). Am J Surg Pathol, 2002,26:1553-1566
34. Mosquera JM, Dal Cin P, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol, 2011,20:129-137
35. Numakura K, Tsuchiya N, Yuasa T, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol, 2011,16:577-580
36. Hou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig, 2010,30:799-804
37. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer, 2010,116:5219-5225
38. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol, 2010,21:1834-1838
39. Tickoo SK, Reuter VE, Amin MB, et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol, 1999,23:1094-1101
40. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol, 2002,26:1542-1552
41. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet, 2005,76:1023-1033
42. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch, 2010,456:355-365
43. Waldert M, Klatte T, Haitel A, et al. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol, 2010,57:661-665
44. Bex A. Editorial comment on: hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol, 2010,57:665
45. Adley BP, Smith ND, Nayar R, et al. Birt-Hogg- Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med, 2006,130:1865-1870.